From the Human Genome Sciences and IPSOS (Dr Narayanan), Rockville, MD; Truven Health Analytics (Ms Wilson, Mr Juneau, and Dr Durden), Washington, DC; and GlaxoSmithKline (Mr Ogelsby) Raleigh Durham, NC.
J Occup Environ Med. 2013 Nov;55(11):1262-70. doi: 10.1097/JOM.0000000000000008.
To estimate the medical and productivity-related cost burden of systemic lupus erythematosus (SLE) flares and comorbidities in a commercially insured population.
Using administrative data, annual medical costs and indirect costs because of work loss were calculated for adult SLE patients, including flare severity and SLE-related comorbidity subsets, and a matched control group without SLE.
Adjusted annualized medical costs were $18,952, $4305, $914, and $441 greater for SLE patients with severe, moderate, mild, and no flares, respectively, during follow-up than those of the matched controls. Medical costs also varied by SLE-related comorbidity. Adjusted annualized indirect costs of work loss because of absence and short-term disability were $1867 and $1602 greater, respectively, for SLE patients than for controls.
SLE imposes a substantial cost burden to both patients and their employers.
评估系统性红斑狼疮（SLE）发作和合并症在商业保险人群中的医疗和生产力相关成本负担。
使用行政数据，计算了成年 SLE 患者的年度医疗费用和因工作损失导致的间接费用，包括发作严重程度和 SLE 相关合并症亚组，以及无 SLE 的匹配对照组。
与匹配对照组相比，在随访期间，严重、中度、轻度和无发作的 SLE 患者的调整后年化医疗费用分别高出 18952 美元、4305 美元、914 美元和 441 美元。医疗费用也因 SLE 相关合并症而异。由于缺勤和短期残疾，SLE 患者的调整后年化间接工作损失成本分别比对照组高出 1867 美元和 1602 美元。
SLE 给患者及其雇主带来了巨大的成本负担。
Zotero 插件